NCT02091869

Brief Summary

The purpose of this study is to see if using a mobile phone application asthma action plan will help improve asthma management.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at below P25 for not_applicable asthma

Timeline
Completed

Started Mar 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

March 1, 2014

Completed
18 days until next milestone

First Posted

Study publicly available on registry

March 19, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
1.9 years until next milestone

Results Posted

Study results publicly available

February 23, 2017

Completed
Last Updated

June 29, 2018

Status Verified

June 1, 2018

Enrollment Period

1.1 years

First QC Date

January 14, 2014

Results QC Date

June 20, 2016

Last Update Submit

June 27, 2018

Conditions

Keywords

AdolescentsAsthmaAsthma Symptoms

Outcome Measures

Primary Outcomes (1)

  • Change in Asthma Control Test Scores

    The Asthma Control Test™ (ACT) is a 5 question health survey used to measure asthma control in individuals 12 years of age and older. The total sum scores range from 5-25. Higher scores mean that asthma is more controlled. The ACT is an efficient, reliable, and valid method of measuring asthma control, with or without, lung functioning measures such as spirometry. ACT helps identify and detect asthma patients who are not well controlled. ACT scores were examined pre- and post-intervention. A score total of 19 or less means asthma may not be well controlled. The timeframe is during the past 4 weeks. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5).

    Baseline and Six months

Secondary Outcomes (1)

  • Change in Asthma Self-Efficacy Scores

    Baseline and Six months

Other Outcomes (1)

  • Comparison of Participant Usage Rates Between Mobile and Paper Asthma Action Plans

    Six months

Study Arms (2)

Paper Asthma Action Plan

EXPERIMENTAL

Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.

Other: Paper Asthma Action Plan

Mobile Phone

EXPERIMENTAL

Participants will record asthma symptoms, medication usage, and peak flow data on their phones.

Device: Mobile Phone

Interventions

Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.

Paper Asthma Action Plan

Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.

Also known as: IPhone and Android mobile phones
Mobile Phone

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Age ≥ 12 and ≤ 17 years.
  • Access to Apple or Android based smart phone
  • Mild to severe persistent asthma or poorly controlled asthma (see definitions below).
  • o A different assessment of eligibility will be performed depending on whether or not the parent reports use of a preventive asthma medication at baseline. This is consistent with 2007 National Asthma Education Prevention Program recommendations that make a strong distinction between classifying asthma severity (for children not using preventive medications) and assessing control (for children using preventive medications). If a child has used a preventive medication in the past, but reports no use of the medication in the prior 3 months, we will assess severity.)
  • Children not using a preventive medication at baseline: Assess for mild persistent to severe persistent asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine severity:
  • An average of \>2 days per week with asthma symptoms
  • \>2 days per week with rescue medication use
  • ≥2 nights per month awakened with nighttime symptoms
  • Minor limitation of activity
  • ≥2 episodes of asthma during the past year that have required systemic corticosteroids
  • Children using a preventive medication at baseline: Assess for poorly controlled asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine control:
  • An average of \>2 days per week with asthma symptoms
  • \>2 days per week with rescue medication use
  • ≥2 nights per month awakened with nighttime symptoms
  • Some limitation of activity
  • +1 more criteria

You may not qualify if:

  • Significant underlying respiratory disease other than asthma (such as cystic fibrosis or chronic lung disease) that could potentially interfere with asthma-related outcome measures.
  • Significant co-morbid conditions (such as moderate to severe developmental delay, i.e. special education classroom or diagnosis) that could preclude participation in an education-based intervention.
  • Inability to speak or understand English (child or parent).
  • Children in foster care or other situations in which consent cannot be obtained from a guardian.
  • Prior enrollment in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arkansas Children's Hospital Research Institute

Little Rock, Arkansas, 72202, United States

Location

Related Publications (8)

  • Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, Scalia MR, Akinbami LJ; Centers for Disease Control and Prevention (CDC). National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ. 2007 Oct 19;56(8):1-54.

    PMID: 17947969BACKGROUND
  • Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics. 2009 Mar;123 Suppl 3:S131-45. doi: 10.1542/peds.2008-2233C.

    PMID: 19221156BACKGROUND
  • Forero R, Bauman A, Young L, Larkin P. Asthma prevalence and management in Australian adolescents: results from three community surveys. J Adolesc Health. 1992 Dec;13(8):707-12. doi: 10.1016/1054-139x(92)90068-m.

    PMID: 1290773BACKGROUND
  • Kyngas HA. Compliance of adolescents with asthma. Nurs Health Sci. 1999 Sep;1(3):195-202. doi: 10.1046/j.1442-2018.1999.00025.x.

    PMID: 10894643BACKGROUND
  • Braun-Fahrlander C, Gassner M, Grize L, Minder CE, Varonier HS, Vuille JC, Wuthrich B, Sennhauser FH. Comparison of responses to an asthma symptom questionnaire (ISAAC core questions) completed by adolescents and their parents. SCARPOL-Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with respect to Air Pollution. Pediatr Pulmonol. 1998 Mar;25(3):159-66. doi: 10.1002/(sici)1099-0496(199803)25:33.0.co;2-h.

    PMID: 9556007BACKGROUND
  • Venn A, Lewis S, Cooper M, Hill J, Britton J. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. BMJ. 1998 Jun 27;316(7149):1945-6. doi: 10.1136/bmj.316.7149.1945. No abstract available.

    PMID: 9641931BACKGROUND
  • Calmes D, Leake BD, Carlisle DM. Adverse asthma outcomes among children hospitalized with asthma in California. Pediatrics. 1998 May;101(5):845-50. doi: 10.1542/peds.101.5.845.

    PMID: 9565412BACKGROUND
  • Perry TT, Marshall A, Berlinski A, Rettiganti M, Brown RH, Randle SM, Luo C, Bian J. Smartphone-based vs paper-based asthma action plans for adolescents. Ann Allergy Asthma Immunol. 2017 Mar;118(3):298-303. doi: 10.1016/j.anai.2016.11.028. Epub 2017 Jan 19.

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Limitations and Caveats

There were not limitations and caveats.

Results Point of Contact

Title
Dr. Tamara T. Perry
Organization
University of Arkansas for Medical Sciences

Study Officials

  • Tamara T Perry, MD,FAAP

    University of Arkansas

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2014

First Posted

March 19, 2014

Study Start

March 1, 2014

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

June 29, 2018

Results First Posted

February 23, 2017

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

There is no plan to share individual participant data.

Locations